ZDHHC17 Antibody

What is ZDHHC17 and why is it important in research?

ZDHHC17 (also known as HIP14 or Huntingtin-interacting protein 14) is a zinc finger DHHC-type containing protein that functions as a palmitoyltransferase. It catalyzes the addition of palmitate onto various protein substrates and is involved in a variety of cellular processes . ZDHHC17 is critically important in research because:

• It regulates post-translational modification by the lipid palmitate, which is crucial for the correct targeting and function of many proteins

• It interacts with huntingtin protein, which is implicated in Huntington's disease

• It has been identified as a potential drug target for viral infections such as SADS-CoV

• It plays a significant role in glioblastoma development through the JNK/p38 pathway

ZDHHC17 is primarily localized in the Golgi apparatus, and its deficiency leads to arrest at the G2/M transition in the cell cycle .

What applications are ZDHHC17 antibodies validated for?

ZDHHC17 antibodies have been validated for multiple experimental applications:

Researchers should note that optimal dilutions may vary depending on the specific antibody product and experimental conditions. It is recommended that each reagent should be titrated in the testing system to obtain optimal results .

What species reactivity can I expect from ZDHHC17 antibodies?

Based on available commercial antibodies, ZDHHC17 antibodies show reactivity with:

• Human samples (validated across multiple antibodies)

• Mouse samples (validated and predicted)

• Rat samples (validated and predicted)

Some antibodies also predict cross-reactivity with additional species:

• Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, and Chicken (predicted based on sequence homology)

The high conservation of ZDHHC17 across mammalian species (up to 100% sequence similarity in certain regions) explains this broad cross-reactivity .

How should I optimize Western blot protocols for ZDHHC17 detection?

For optimal Western blot detection of ZDHHC17:

• Sample preparation:

  • ZDHHC17 has been successfully detected in various samples, including Raji cells and human kidney tissue

  • Use appropriate lysis buffers that maintain protein integrity while effectively extracting membrane proteins

• Antibody selection and dilution:

  • Use validated antibodies at recommended dilutions (typically 1:500-1:1000)

  • The observed molecular weight is approximately 70-73 kDa, which closely matches the calculated molecular weight of 73 kDa

• Blocking and detection:

  • Standard blocking procedures with either BSA or non-fat milk are typically effective

  • Both chemiluminescent and fluorescent secondary detection systems can be used

• Controls:

  • Include positive controls such as Raji cells or human kidney tissue extracts

  • For validation studies, considering using ZDHHC17 knockout cells as negative controls, as has been done in published research

What are the best practices for immunohistochemical detection of ZDHHC17?

For successful immunohistochemical detection of ZDHHC17:

• Tissue preparation and antigen retrieval:

  • ZDHHC17 has been successfully detected in human testis tissue

  • Recommended antigen retrieval: Use TE buffer pH 9.0

  • Alternative: citrate buffer pH 6.0 may also be effective

• Antibody dilutions:

  • Use antibody at dilutions of 1:20-1:200, depending on the specific product

  • Titrate the antibody in your specific system to determine optimal concentration

• Detection system:

  • Both DAB-based and fluorescent detection systems can be used

  • For co-localization studies (e.g., with Golgi markers), fluorescent methods are preferred

• Expression pattern interpretation:

  • ZDHHC17 is expressed in all brain regions, with highest expression in the cortex, cerebellum, occipital lobe and caudate

  • Expression is also seen in testis, pancreas, heart and kidney

  • Expect primarily Golgi apparatus localization in most cell types

How can ZDHHC17 antibodies be used in studying palmitoylation mechanisms?

ZDHHC17 antibodies can be powerfully applied to palmitoylation research through:

• Co-immunoprecipitation studies:

  • Use ZDHHC17 antibodies to pull down the enzyme and identify interacting substrates

  • This approach has identified various neuronal proteins, including SNAP25, DLG4/PSD95, GAD2, SYT1 and HTT as ZDHHC17 substrates

• Domain-function analysis:

  • ZDHHC17 contains two key domains: the DHHC cysteine-rich domain (required for palmitoylation activity) and ankyrin repeat motifs (ANK, involved in substrate recruitment)

  • Use domain-specific antibodies to distinguish the roles of these domains

• Palmitoylation inhibition studies:

  • Compare ZDHHC17 knockout/knockdown effects with chemical inhibition using 2-bromopalmitate (2-BP)

  • Research has shown that 2-BP significantly suppresses SADS-CoV infection, linking ZDHHC17 function to viral replication

• Functional analysis of substrate specificity:

  • Unlike other ZDHHC family members, ZDHHC17 has broader fatty acid selectivity and can transfer myristate and stearate in addition to palmitate

  • Antibodies can help track enzyme location and expression when studying these alternative acylation reactions

What role does ZDHHC17 play in viral infections, and how can antibodies help study this?

ZDHHC17 has been identified as a host dependency factor for viral infections, particularly for SADS-CoV:

• Genome-wide CRISPR screening:

  • ZDHHC17 was identified as an important host factor for SADS-CoV infection through CRISPR knockout library screening

  • Antibodies can validate screening results by confirming knockout efficiency

• Viral replication mechanisms:

  • ZDHHC17 knockout cells showed significantly decreased SADS-CoV RNA copies and nucleocapsid protein expression

  • Antibodies against viral proteins and ZDHHC17 can be used in co-localization studies to understand the spatial relationships during infection

• Domain-specific functions in viral replication:

  • Research has demonstrated that the DHHC domain of ZDHHC17 is required for SADS-CoV replication

  • Domain-specific antibodies can help elucidate the precise mechanisms

• Therapeutic target validation:

  • The palmitoylation inhibitor 2-BP significantly reduces SADS-CoV replication, suggesting ZDHHC17 as a potential drug target

  • Antibodies can be used to assess ZDHHC17 expression levels and localization in response to potential inhibitors

How is ZDHHC17 involved in cancer biology, particularly glioblastoma?

ZDHHC17 plays significant roles in cancer development, particularly in glioblastoma (GBM):

• Expression profile analysis:

  • ZDHHC17 is upregulated in GBM compared to normal brain tissue

  • Antibodies can be used in tissue microarrays to analyze expression patterns across tumor grades and subtypes

• Signaling pathway interactions:

  • ZDHHC17 interacts with MAP2K4 through its N-terminal ankyrin domain to form a signaling module that activates the JNK/p38 pathway

  • This activation is independent of its palmitoyltransferase (PAT) activity

  • Co-immunoprecipitation with ZDHHC17 antibodies can help identify and validate novel interaction partners

• Cell cycle regulation:

  • ZDHHC17 deficiency leads to arrest at the G2/M transition, along with an increase in the proportion of cells with dense Golgi

  • Antibodies can be used in cell synchronization studies to track ZDHHC17 expression and localization through the cell cycle

• Therapeutic implications:

  • Glioma cells with suppressed ZDHHC17 expression are insensitive to 2-BP inhibition

  • Antibodies can help stratify tumors based on ZDHHC17 expression to predict potential treatment responses

Why might I observe multiple bands when using ZDHHC17 antibodies in Western blot?

Multiple bands in ZDHHC17 Western blots may occur due to:

• Post-translational modifications:

  • ZDHHC17 itself can undergo palmitoylation and other modifications

  • These modifications may alter protein mobility in SDS-PAGE

• Alternative splicing:

  • Different ZDHHC17 isoforms may be expressed in various tissues

  • The calculated molecular weight is 73 kDa, but the observed weight is often around 70 kDa

• Proteolytic degradation:

  • Ensure complete protease inhibition during sample preparation

  • Fresh preparation or proper storage of samples is critical

• Antibody specificity issues:

  • Different epitopes may be recognized by different antibodies

  • Consider using antibodies targeting different regions of ZDHHC17 to confirm specificity

  • The N-terminal region (amino acids 3-37) and middle region antibodies are commonly used

How can I validate ZDHHC17 antibody specificity for my experiments?

Rigorous validation of ZDHHC17 antibody specificity can be achieved through:

• Genetic approaches:

  • Use ZDHHC17 knockout cells as negative controls, which should show absence of specific signal

  • Use cells overexpressing ZDHHC17 (wild-type or tagged versions) as positive controls

• Blocking peptide experiments:

  • Pre-incubate the antibody with the immunizing peptide

  • This should abolish specific binding if the antibody is truly specific

  • Peptide-antibody pairs are available for this purpose

• Domain-specific validation:

  • Test antibody reactivity against truncation mutants lacking specific domains (ΔANK or ΔDHHC)

  • This can confirm the epitope location and antibody specificity

• Cross-species validation:

  • If the antibody is expected to be cross-reactive, test it on samples from multiple species

  • ZDHHC17 is highly conserved across mammalian species, with up to 100% sequence similarity in certain regions

What are the key considerations when designing immunocytochemistry experiments with ZDHHC17 antibodies?

For successful immunocytochemistry with ZDHHC17 antibodies:

• Subcellular localization expectations:

  • ZDHHC17 is primarily localized to the Golgi apparatus

  • Also found in cytoplasmic vesicle membranes

  • Co-staining with Golgi markers (e.g., GM130) is recommended for verification

• Fixation and permeabilization:

  • For membrane proteins like ZDHHC17, fixation method significantly impacts antigen detection

  • Paraformaldehyde fixation (4%) followed by mild detergent permeabilization often works well

  • Consider testing multiple permeabilization methods if signal is weak

• Antibody concentration and incubation:

  • Starting dilutions similar to IHC (1:20-1:200) are reasonable, but require optimization

  • Longer incubation times (overnight at 4°C) may improve specific signal

• Controls and validation:

  • Include cells with known ZDHHC17 expression profiles as positive controls

  • Knockout or knockdown cells provide excellent negative controls

  • Secondary-only controls are essential to confirm absence of non-specific binding

How are ZDHHC17 antibodies being used to study neurological disorders?

ZDHHC17 antibodies are valuable tools in neurological disorder research:

• Huntington's disease studies:

  • ZDHHC17 (HIP14) regulates palmitoylation and distribution of huntingtin protein

  • Antibodies can track alterations in ZDHHC17-huntingtin interactions in disease models

• Expression pattern analysis in brain tissues:

  • ZDHHC17 is expressed in all brain regions, with highest expression in the cortex, cerebellum, occipital lobe and caudate

  • Antibodies can reveal altered expression patterns in neurological disorders

• Substrate identification in neuronal tissues:

  • ZDHHC17 is a palmitoyltransferase specific for neuronal proteins like SNAP25, DLG4/PSD95, GAD2, SYT1

  • Co-immunoprecipitation with ZDHHC17 antibodies can identify novel neuronal substrates

• Therapeutic target assessment:

  • As palmitoylation dysregulation is implicated in various neurological disorders, ZDHHC17 represents a potential therapeutic target

  • Antibodies can help evaluate the effects of candidate compounds on ZDHHC17 expression and localization

What new insights about ZDHHC17 function are being uncovered through antibody-based research?

Recent antibody-based research is revealing new ZDHHC17 functions:

• Cell cycle regulation:

  • ZDHHC17 deficiency leads to arrest at the G2/M transition

  • Antibodies in cell synchronization studies are helping elucidate the mechanisms

• Non-palmitoyltransferase functions:

  • The JNK/p38 activation promoted by ZDHHC17 in glioma is independent of its palmitoyltransferase activity

  • Domain-specific antibodies help distinguish enzymatic from scaffolding functions

• Viral host dependency factor:

  • ZDHHC17 is required for SADS-CoV genomic RNA replication

  • Antibodies help track ZDHHC17 relocalization during viral infection

• Substrate specificity determinants:

  • Unlike other ZDHHC family members, ZDHHC17 has broader fatty acid selectivity

  • Structural and functional studies using antibodies are helping map the determinants of this selectivity

How can multiplexed antibody approaches advance ZDHHC17 research?

Multiplexed antibody approaches offer powerful new insights into ZDHHC17 biology:

• Co-localization studies:

  • Combining ZDHHC17 antibodies with antibodies against substrate proteins reveals spatial relationships

  • Multi-color immunofluorescence can track dynamic changes in these relationships during cellular processes

• Proximity ligation assays:

  • These can detect when ZDHHC17 is in close proximity to potential substrate proteins

  • Useful for confirming direct interactions suggested by co-immunoprecipitation studies

• Single-cell analysis:

  • Antibody-based single-cell techniques can reveal heterogeneity in ZDHHC17 expression

  • Particularly valuable in cancer research, where cellular heterogeneity is common

• Tissue microarrays:

  • High-throughput analysis of ZDHHC17 expression across multiple tissue samples

  • Can correlate expression with clinical outcomes in diseases like glioblastoma where ZDHHC17 is implicated